Table 1. Baseline characteristics of the 26 rheumatoid arthritis patients included in the study.
| TNFi/ Characteristic | Adalimumab (n = 15) | Infliximab (n = 11) | Total (n = 26) |
|---|---|---|---|
| Male gender, n (%) | 4 (27) | 4 (36) | 8 (31) |
| Age, years | 53 (39–64) | 54 (49–61) | 54 (41–61) |
| IgM-RF positive, n (%) | 11 (73) | 8 (73) | 19 (73) |
| Previous biological DMARD, n (%) | 5 (33) | 2 (18) | 7 (27) |
| Concomitant MTX, n (%) | 7 (47) | 8 (72) | 15 (58) |
| MTX, mg/week | 17.5 (10–20) | 17.5 (11.25–23.75) | 17.5 (10–20) |
| Disease duration, years | 5 (2–16) | 6 (2–10) | 6 (2–12) |
| DAS28(CRP) | 5.0 (4.2–5.4) | 5.3 (4.4–6.0) | 5.0 (4.3–5.8) |
| No. of tender joints | 8 (5–16) | 8 (4–17) | 8 (5–16) |
| No. of swollen joints | 6 (2–8) | 4 (2–7) | 5 (2–8) |
| CRP, mg/ml | 6.0 (2.0–34.0) | 4.0 (1.0–36.0) | 5.0 (1.8–36.0) |
| IL-6 pg/ml | 8 (1–26) | 7 (1–40) | 8 (1–36) |
| sTNF-R1 pg/ml | 1105 (946–1340) | 1201 (1006–1481) | 1152 (976–1380) |
| sTNF-R2 pg/ml | 3100 (2777–3750) | 2981 (2143–3750) | 3092 (2642–3750) |
* except when otherwise indicated, values are median (IQR); IgM-RF = IgM rheumatoid factor; DMARD = Disease-modifying antirheumatic drug; DAS28(CRP) = Disease activity score in 28 joints based on C-reactive protein (CRP); MTX = methotrexate.